Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Join | Sign in
Home>Resources>Webcasts>This Webcast
  Webcasts

Novel Histamine Receptor Family Antagonists by Fragment Screening and Molecular Modelling

Mark Slack, Group Leader Cellular Assays, Evotec, speaking at MedChem Europe
Date Posted: Sunday, June 12, 2011
Access to this article and other content is for registered users.

Join the Technology Networks Community

  • Access to the latest scientific news, products and research through Technology Networks
  • Upload and share your posters on ePosters
  • View a library of 1,800+ scientific and medical posters
  • A library of 3,000+ scientific videos on LabTube


Sign In



Forgotten your details? Click Here
If you already have an account with Technology Networks, please use your existing login details. If you do not yet have an account please join here.

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Related Content

Evotec Wins Research Grant to Advance H3 Receptor Antagonist Programme into the Clinic
A EUR 1.5 million BMBF grant will advance the H3 receptor antagonist programme through Phase I clinical studies.
Tuesday, April 27, 2010
Evotec and Boehringer Ingelheim Extend and Broaden Research Collaboration
Strategic research collaboration continues for another 4 years at a value of EUR 15 million plus milestones and royalties
Monday, November 09, 2009
Evotec Receives a EUR 2.5 Million Milestone Payment in its Research Collaboration with Boehringer Ingelheim
Evotec AG today announced that it has achieved another milestone in its research collaboration with Boehringer Ingelheim.
Thursday, October 22, 2009
Procter & Gamble Selects Evotec as Provider of Pharmaceutical Discovery and Chemical Development Services
P&GP will access a wide range of discovery and preclinical expertise offered by Evotec, ranging from assay development, screening, medicinal and computational chemistry to scale-up and pharmaceutical manufacture.
Monday, July 25, 2005
Evotec OAI and Novartis Pharma AG Sign Lead Discovery Collaboration

Thursday, April 10, 2003
Evotec OAI collaboration with KeyNeurotek and IMTM

Wednesday, January 15, 2003
Evotec OAI Names President of Discovery Services

Tuesday, December 10, 2002
Evotec OAI Enters into Agreement With Venture Capital Firm

Thursday, November 14, 2002
Scientific News
Label-Free Binding Analysis Trends
Understand current trends and learn which application areas are expected to gain in popularity over the next few years.
Potential New Class of Cancer Drugs
Scientists have found a way to stop cancer cell growth by targeting the Warburg Effect, a trait of cancer cell metabolism that scientists have been eager to exploit.
Global Search for Next Antibiotic
University of Queensland researchers have launched a global search to discover antibiotics capable of combating superbug bacteria that are resistant to current antibiotics.
New Clue to How Cancer Causes Organ Failure
New findings from a research group at Uppsala University show that the neutrophil, a type of blood cell, plays an important role in the process of induced organ failure.
Tackling Chemical Safety Rules and Regulations
Helsinki Chemicals Forum continues to lead international chemicals safety and management discussions.
Pioneering New Method to Map Enzyme Activity
Cardiff University researchers new discovery could have wide-reaching implications for the creation of manufactured goods, biofuels and therapeutic drugs.
Seashells to Deliver New Drugs and Vaccines
Australian scientists have developed a protective seashell-inspired capsule to preserve the active biological ingredients needed to create new drugs.
Euro Vision turns Reality for Australia’s Iconic ‘Green Whistle’
Patients will soon benefit from a unique invention, with emergency pain killer Penthrox receiving initial regulatory approval for sale in the European and UK markets.
New Type of Drug Can Target All Disease-causing Proteins
Current drugs block the actions of only about a quarter of known disease-causing proteins, but Yale University researchers have developed a technology capable of not just inhibiting, but destroying every protein it targets.
Laser Technique for Self-Assembly of Nanostructures
Researchers have developed a low-cost technique that holds promise for a range of scientific and technological applications.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters